由于第一期和第二期试验中EDG-7500治疗心脏的早期结果呈阳性,Edgewise Therapeutics的股份增长了39.3%. Edgewise Therapeutics shares rise 39.3% on positive early results for heart treatment EDG-7500 in Phase 1 and 2 trials.

由于其用于阻塞性高性心肌病 (HCM) 的心脏治疗EDG-7500的早期积极结果,Edgewise Therapeutics (NASDAQ: EWTX) 的股价上39.3%,至26.58美元. Edgewise Therapeutics (NASDAQ: EWTX) shares rose 39.3% to $26.58 following positive early results for its heart treatment EDG-7500, designed for obstructive hypertrophic cardiomyopathy (HCM). 在第一阶段和第二阶段试验中,该药物显示左心室外流压力梯度和NT-ProBNP水平显著下降,表明心脏病发病率有所改善,对生命迹象或左心室功能没有不利影响。 In Phase 1 and Phase 2 trials, the drug showed significant reductions in left ventricular outflow tract pressure gradients and NT-proBNP levels, indicating heart failure improvement, with no adverse effects on vital signs or left ventricular function. 预计2025年初会有进一步的数据。 Further data is expected in early 2025.